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Osteogenesis imperfecta (OI) can be a severe disorder that can be diagnosed before birth.
Transplantation of mesenchymal stem cells (MSC) has the potential to improve the bone
structure, growth, and fracture healing. In this review, we give an introduction to OI and
MSC, and the basis for pre- and postnatal transplantation in OI. We also summarize the
two patients with OI who have received pre- and postnatal transplantation of MSC. The
findings suggest that prenatal transplantation of allogeneic MSC in OI is safe. The cell
therapy is of likely clinical benefit with improved linear growth, mobility, and reduced
fracture incidence. Unfortunately, the effect is transient. For this reason, postnatal booster
infusions using same-donor MSC have been performed with clinical benefit, and without
any adverse events. So far there is limited experience in this specific field and proper
studies are required to accurately conclude on clinical benefits of MSC transplantation to
treat OI.
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OSTEOGENESIS IMPERFECTA
Osteogenesis imperfecta (OI), or brittle bone disease, is a group
of genetic disorders caused mainly by defects in collagen synthesis
(Forlino and Marini, 2000). The majority of OI cases are caused
by some 1500 different dominant mutations in the COL1A1 or
COL1A2 gene, resulting in abnormal assembly of the protein
(Canty and Kadler, 2005). More recently, recessive forms for OI
has been described, where defects in proteins involved in post-
translational modifications or transport leading to perturbations
of the collagen 3-hydroxylation complex (Barnes et al., 2010), and
collagen chaperone pathways (Alanay et al., 2010; Christiansen
et al., 2010). OI presents in a clinically heterogenous manner,
ranging from the mild type I, to the progressively deforming type
III and the perinatally lethal type II according to the original
Sillence classification (Sillence et al., 1979). An evolving under-
standing of the genetics has now made it possible to consider
refining and adding to the original Sillence classification (Forlino
et al., 2011).
Currently, the goal of clinical management is to optimize the
patient’s gross motor abilities and to achieve a level of inde-
pendence during childhood life. This is largely accomplished
empirically through physical rehabilitation and life-long ortho-
pedic interventions in correcting bony deformities of the long
bones and vertebra (Laron and Pandya, 2013). Pharmacological
intervention is underpinned by the use of bisphosphonates in an
effort to reduce bone resorption and increase bone mineralization
(Rauch and Glorieux, 2006). While mineralization has been
shown to improve with bisphosphonate treatment, a recent meta-
analysis of randomized trials failed to demonstrate consistent
benefits in fracture rates, reduction of pain, or functional mobility
(Dwan et al., 2014). Moreover, there is a growing concern on
the role of bisphosphonates in impairing bone remodeling in
these children (Marini, 2009). Growth hormones have also been
evaluated, and have shown encouraging benefits in the increase in
linear growth (Antoniazzi et al., 1996), and are being considered
for treatment in combination with bisphosphonates (Antoniazzi
et al., 2010).
Due to the lack of effectiveness in current modalities of treat-
ment, which does not address the underlying molecular defect,
alternative approaches are currently being explored. Some of these
experimental treatments include allogeneic cell transplantation
(Horwitz et al., 1999, 2001, 2002; Otsuru et al., 2012). The genetic
defect may be corrected through homologous recombination of
the patient’s stem cells (Chamberlain et al., 2004), or through
the degradation of abnormal COL1A1/2 transcripts (Millington-
Ward et al., 1997, 2002). In this paper, we will focus on the use of
allogeneic mesenchymal stem cells (MSC) in pre- and postnatal
treatment of OI.
MESENCHYMAL STEM CELLS AS DONOR CELLS IN OI
Mesenchymal stem cells are stromal cells that have been orig-
inally identified from the adherent portion of bone marrow
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(Friedenstein et al., 1966, 1968). They grow as spindle shaped
cells displaying colony-forming capacity in low density cultures
and are non-hematopoietic and non-endothelial. MSC can be
propagated through multiple passages in cell culture and differen-
tiate down the standard osteogenic, adipogenic and chondrogenic
lineages under permissive conditions (Pittenger et al., 1999).
MSC do not express human leukocyte antigen (HLA) class II
antigens, and are generally considered to be non-immunogenic
in nature and possess immune-modulatory properties (Le Blanc,
2003). Although attempts at standardizing the nomenclature of
what constitute a MSC has been proposed by the International
Society of Cellular Therapy (Dominici et al., 2006), evidence of
bona fide stem cell properties had only been demonstrated in
CD146 positive perivascular cells in human bone marrow with
in vivo self-renewal properties (Sacchetti et al., 2007). Over the
past couple of decades, the isolation of MSC-like cells has been
reported from multiple organs and tissues (da Silva Meirelles
et al., 2006), which may originate from NG2 (neuron-glial antigen
2) and CD146 positive pericytes (Crisan et al., 2008), although
non-bone marrow-derived MSC have yet to be validated for
stemness.
As MSC are readily isolated and expanded, are non-
immunogenic and have multilineage differentiation capacity, they
have been studied and indeed trialed clinically in a diverse range
of clinical scenarios ranging from the treatment of graft versus
host disease (Le Blanc et al., 2008), autoimmune diseases such as
Crohn’s disease (Uccelli et al., 2008; Uccelli and Prockop, 2010),
cardiovascular diseases like acute myocardial infarction and stroke
and orthopedic applications including bone and cartilage repair
(Zhang et al., 2012). However, MSC have limited ability to be
expanded under standard conditions especially with increasing
age (Siegel et al., 2013; Choudhery et al., 2014), rapidly senescing
in culture and with restrictions in multilineage differentiation
capacity (Digirolamo et al., 1999; Muraglia et al., 2000). In addi-
tion, MSC yield, growth kinetics and differentiation capabilities
vary significantly between individuals, restricting their clinical
utility (Javazon et al., 2004).
Another class of MSC has been characterized in fetal and
perinatal life, initially from first trimester tissues (Campagnoli
et al., 2001; Gotherstrom et al., 2003; Chan et al., 2008), and
have now been found in multiple tissue types including the
umbilical cord, placenta, and amniotic fluid (O’Donoghue and
Chan, 2006; De Coppi et al., 2007). These primitive MSC types
have been found in higher frequencies with a higher colony-
forming capacity, having longer telomeres and a higher prolif-
erative potential (Chan et al., 2005; Guillot et al., 2007), and
differentiate more readily into bone and muscle (Chan et al.,
2006, 2007; De Coppi et al., 2007; Zhang et al., 2009), and non-
mesenchymal lineages such as neural and hepatic cells (De Coppi
et al., 2007; Kennea et al., 2009). Like their adult counterparts,
human fetal MSC (hfMSC) are also non-immunogenic, and have
the ability to modulate immune responses (Gotherstrom et al.,
2003, 2004; Gotherstrom, 2007; Di Trapani et al., 2014). Given
the ability of hfMSC to be expanded several fold more efficiently
than adult MSC, their enhanced colony-forming capacity and
increased bone differentiation capacity, they may be the ideal cell
type for treatment of OI.
The rationale for the use of allogeneic MSC for the treatment
of OI is underpinned by the ability of MSC to home to bone
(Pereira et al., 1995; Guillot et al., 2008) and indeed to regions of
active remodeling as found in fracture sites and in patients with
OI. MSC secretes both paracrine growth factors and normal type
I collagen conducive for generating normal bone tissues and thus
ameliorating the bone fragility phenotype in OI.
PRENATAL TRANSPLANTATION
Skeletal dysplasia occurs in fetal life, which can be diagnosed read-
ily through mid-trimester fetal anomaly scans (Schramm et al.,
2009; Barkova et al., 2014). Affected fetuses may present with
shortened long bones and the occurrence of multiple fractures,
alerting the clinician toward a diagnosis of OI. Definitive prenatal
genetic diagnosis may be achieved through standard amniocen-
tesis or fetal blood sampling, both of which are established fetal
medicine procedures largely available in most developed coun-
tries. This opens up the possibility of offering prenatal treatment.
In the context of OI, the most convincing argument for prena-
tal transplantation would be to ameliorate the disease process at
a time of rapid skeletal development where spontaneous fractures
are occurring. Other arguments in favor of a prenatal approach
includes (i) the relatively smaller cell doses required due to the
size of the fetus, (ii) the shunting of the intravenously delivered
cells to the arterial circulation through the patent foramen ovale
in fetal life rather than being trapped in the lungs in postnatal
life, and (iii) possibly the lower risks of immune rejection in
the developing immune system of the recipient (Lee et al., 2009;
Mattar et al., 2012).
PRENATAL TRANSPLANTATION IN ANIMAL MODELS OF
OSTEOGENESIS IMPERFECTA
Experimental evidence of the efficacy of prenatal MSC transplan-
tation was provided by Guillot and colleagues, who tested the
ability of first trimester fetal blood-derived MSC to ameliorate OI
in the oim mouse, a naturally occurring recessive mouse model
approximating human type III OI, with progressive deformities
and skeletal fractures (Chipman et al., 1993). In this model, 106
culture expanded hfMSC were injected intraperitoneally at E14
gestation (a high dose of around 109/kg fetal weight) and allowed
to litter naturally in this xenogeneic transplantation model in a
fully immune-competent recipient (Guillot et al., 2008). Donor
cells engrafted in a wide range of tissues such as the skin, heart,
lung, brain, and thymus, but were found in greater quantities
in skeletal tissues where up to 5% of cells were of donor origin.
Human donor cells expressing the bone marker osteopontin
tended to cluster around areas of active bone formation and at
fracture sites. Transplanted mice demonstrated improved bone
strength, length, and cortical thickness, with a two-third reduc-
tion in fractures (Guillot et al., 2008).
More recently, Panaroni et al. (2009) investigated the ability
of prenatal allogeneic bone marrow transplantation in the BrtlIV
mouse, a dominant model of OI more reflective of human type
II OI. Here, 5 × 106 unmanipulated bone marrow from adult
donors was transplanted intraperitoneally to E13.5–E14.5 fetuses
where wild type females were mated with heterozygous BrtlIV
males, which should produce affected fetuses in half the litter.
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The transplantation resulted in rescue of perinatal lethality, as
transplanted mice had a higher proportion of surviving BrtlIV
offspring. At 2 months of age, only 64% of transplanted mice
were chimeric for donor cells in multiple hematopoietic tissues
including bone marrow where donor cells accounted for 1–2% of
all cells, and produced up to 20% of the bone collagen. Donor
cells were found in clusters in long bones, with accompanying
improvement in bone mineral density and cortical thickness in
treated compared to untreated BrtlIV mice. Thus, these two
models provide evidence supporting a prenatal approach to treat
of OI, leading to higher engraftment rates, amelioration of disease
phenotype and rescue of perinatal lethality. In addition, data
from the BrtlIV mouse study suggests that significant amount
of normal collagen can be deposited by a relatively small pop-
ulation of chimeric donor cells. This would explain the marked
improvements in mineralization and growth seen in the clinical
transplantation cohort where engraftment levels are generally
around 1%.
CLINICAL EXPERIENCE OF POSTNATAL CELL
TRANSPLANTATION IN OSTEOGENESIS IMPERFECTA
The first clinical proof of principle of an allogeneic stem cell trans-
plantation approach came from Horwitz and colleagues where
children affected with type III OI underwent transplantation
with unmanipulated bone marrow from HLA-identical or single-
antigen-mismatched siblings after ablative conditioning therapy.
The treated children exhibited increased linear growth velocities
and reduced fracture frequencies in spite of the low frequency
(<2%) of donor osteoblast engraftment in the bone (Horwitz
et al., 1999, 2001). The same group carried out further clinical
studies with MSC isolated from the same bone marrow donors.
This study included six children at age 2–4 years that received two
infusions of 1 − 5 × 106/kg HLA-matched gene marked adult
MSC. It resulted in MSC engraftment and an increase in linear
growth velocities (Horwitz et al., 2002). Thus, it was established
here that allogeneic MSC infusion is safe in the context of OI,
with donor cells engrafting in bone and results in an increase in
mineralization and growth velocity, albeit only for a limited time.
Although the same group later showed that the origin of donor
blasts might be from the non-adherent fraction of bone marrow,
i.e., the hematopoietic stem cells, rather than the adherent frac-
tion from where MSC are generally isolated (Otsuru et al., 2012).
Not withstanding that, MSC can contribute to bone growth and
mineralization, possibly through secreted growth factors (Otsuru
et al., 2012). Moreover, it would be inconceivable to put a child
through a bone marrow transplantation procedure with all its
attendant morbidity and mortality when the use of non-matched
MSC would obviate the need for conditioning therapy, and have
shown an excellent safety profile through thousands of clinical
infusions (Aguilar et al., 2007; Zhang et al., 2012).
CLINICAL EXPERIENCE OF PRENATAL MSC
TRANSPLANTATION IN OSTEOGENESIS IMPERFECTA
Promising results of tissue repair in animal studies have led to
numerous clinical studies using MSC to treat severe disorders and
several reports indicate a role for MSC therapy in the treatment of
OI both pre- and postnatally. As described above, Horwitz et al.
(2002) performed the first study using HLA-matched MSC to
treat OI postnatally. Results were promising showing low toxicity,
engrafted donor cells and accelerated growth. Encouraged by this
study, prenatal transplantation using hfMSC has since then been
reported in two cases of OI.
The first case presented at gestational week 15 and was later
diagnosed as OI type III, which postnatally was confirmed with
genetic analysis (COL1A2 c.3008G>A; p.Gly1003Asp; Gly913Asp
in the triple helical domain; Le Blanc et al., 2005; Gotherstrom
et al., 2014). At week 24, all limbs were−5 SD and angulated, with
femoral fractures noted. The baby was infused with 6.5 × 106/kg
HLA-unmatched hfMSC at gestational week 31. At 4 months of
age, bisphosphonate treatment was initiated due to presence of
vertebral compression fractures. Until 8 years of age, she was
doing acceptably well with little more than one fracture and one
compression fracture per year (5 femoral, 2 clavicular, 1 shoulder
and 1 skull fracture and 11 vertebral compression fractures).
Remarkably she continued growing and followed her own height
and weight growth curve at −5 SD until the age of 6, when it had
deteriorated to −6.5 SD at the age of 8 years. Due to the increased
fracture rate and declined growth, the patient was transplanted
with 2.8 × 106/kg same-donor cells at the age of 8 years. The
subsequent 2 years after the re-transplantation the patient did not
suffer from any new fractures and the linear growth and mobility
improved (she was able to walk 1000 m without difficulties,
started dance classes, increased her participation in gymnastics at
school). Donor osteoblastic cells were detected in the bone, but
not in any other tissues, at 9 months and 9 years of age. The level
of engraftment was varying, between 0.003 and 16.6%. Only one
other patient is currently known to have an identical COL1A2
mutation and presented with a very severe phenotype of OI. This
patient did not receive MSC therapy and succumbed at 5 months
of age despite postnatal bisphosphonate therapy.
The second case was a baby with OI type IV who presented
with short long bones (<5th centile) and multiple fresh and heal-
ing fractures at 26 weeks of gestation (Gotherstrom et al., 2014).
The baby was transplanted with 30 × 106/kg HLA-unmatched
hfMSC at 31 weeks of gestation, and did not suffer any new
fractures for the remainder of the pregnancy or during infancy.
The patient’s family had a history of short stature and multiple
fractures and genotyping of the patient and family members iden-
tified an autosomal dominant mode of inheritance (c.659G>A;
p.Gly220Asp, Gly130Asp in the triple helical domain). No donor
cells were detected in umbilical cord blood, umbilical cord, and
placenta. There have been no opportunities to obtain bone sam-
ples for analysis in this case. Bisphosphonate therapy was initiated
from 1 month of age due to poor mineralization. The patient
followed her own growth curve until 12 months of age (just
below the 3rd centile), where longitudinal length plateaued. A
postnatal infusion of 10 × 106/kg MSC from the same donor was
performed at 19 months of age, resulting in resumption of her
growth trajectory and she continued to grow just below the 3rd
centile. She started to walk shortly after the transplantation.
Similarly as described in the study by Horwitz and colleagues,
the above described pre- and postnatal transplantations report
a transient clinical effect after hfMSC infusion (Horwitz et al.,
2002; Le Blanc et al., 2005; Gotherstrom et al., 2014), and several
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repeated transplantation might be required during the patients
lifetime, especially in childhood. Nevertheless, intravenous infu-
sion of same-donor hfMSC pre- and postnatally appears safe.
The reported follow-up period is 3–10 years after prenatal trans-
plantation and 2–2.5 years after postnatal transplantation. There
were no signs of any adverse early or late reactions. There was
no alloreactivity of the patient’s lymphocytes detected toward the
donor hfMSC. Before the re-transplantations, analysis showed the
absence of antibodies directed toward HLA class I and II, IgG and
IgM, or fetal bovine serum (FBS).
The cell dose is a critical parameter in cell transplantation
since it may relate to efficacy but a high cell dose may cause
toxicity. In the reported hfMSC transplantations, the cell dose
varied from 5 × 106 to 30 × 106/kg at prenatal transplantation
and from 2.8 × 106 to 10 × 106/kg at postnatal transplantation.
All doses were well tolerated, however, it is unclear from this data
on two patients or from data on adult MSC transplantation for
other disorders if a high cell dose is more efficacious. This remains
to be investigated.
SUMMARY
The two cases described here suggest the safety and feasibility
of prenatal transplantation using HLA-mismatched hfMSC. Fur-
thermore, it suggests a potential benefit to children with OI.
However, the benefit from a single transplant before birth was
transient and subsequent boosters with same-donor cells were
performed with good effect. This is in line with the results from
the study on postnatal MSC therapy in OI by Horwitz et al.
(2002). The summarized data highlights the need to modify the
pre- and postnatal transplant strategies, and possibly the cells, in
order to improve MSC homing and engraftment for better long-
term outcomes.
To accurately evaluate if pre- and postnatal MSC therapy in
OI is an effective treatment, coordinated studies and joint efforts
are necessary. Development of common programs, registries and
guidelines (cell source, isolation and expansion and release crite-
ria, patient inclusion criteria, transplantation strategies, follow-
up measures, etc.), as well as coherence between investigators
within the field is of significant importance. Considering the
complexity of the disease and procedure, we see this as the
only realistic way to proceed if we are to accurately evaluate the
potential of MSC therapy in OI.
The summarized cases demonstrate that prenatal transplan-
tation of allogeneic hfMSC and postnatal boosters using same-
donor cells in OI is safe. The MSC infusions appear to give clinical
benefit, although transiently. However, so far we have limited
experience and further studies are required.
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